Development of a Highly Specific 18 F-Labeled Radioligand for Imaging of the Sigma-2 Receptor in Brain Tumors
Journal of Medicinal Chemistry · 28.09.2023 · 66 (18) · 12840-12857
DOI: 10.1021/acs.jmedchem.3c00735 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 13.09.2023. Verfasst von Tao Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Radiopharmaceuticals (Beijing Normal University), Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 1…. Hauptthemen laut MEDLINE: Receptors, sigma, Fluorine Radioisotopes, Brain Neoplasms, Radiopharmaceuticals. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Novel ligands with the 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline or 5,6-dimethoxyisoindoline pharmacophore were designed and synthesized for evaluation of their structure-activity relationship to the sigma-2 (σ2) receptor and developed as suitable PET radioligands. Compound 1 was found to possess nanomolar affinity (Ki(σ1) = 2.57 nM) for the σ2 receptor, high subtype selectivity (>2000-fold), and high selectivity over 40 other receptors and transporters. Radioligand [18F]1 was prepared with radiochemical yield of 37-54%, > 99% radiochemical purity, and molar activity of 107-189 GBq/μmol. Biodistribution and blocking studies in mice and micro-PET/CT imaging of [18F]1 in rats indicated excellent binding specificity to the σ2 receptors in vivo. Micro-PET/CT imaging of [18F]1 in the U87MG glioma xenograft model demonstrated clear tumor visualization with high tumor uptake and tumor-to-background ratio. Co-injection with CM398 (5 μmol/kg) led to a remarkable reduction of tumor uptake (80%, 60-70 min), indicating high specific binding of [18F]1 in U87MG glioma xenografts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Radiopharmaceuticals (Beijing Normal University), Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China.
- Department of Nuclear Medicine, Xinqiao Hospital, Army Medical University, Chongqing 400037, China.
- Institute of Radiation Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Tianjin 300192, China.
- Department of Nuclear Medicine, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
- Department of Nuclear Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
- Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 04318 Leipzig, Germany.
ORCID-Profile: Leyuan Chen, Hongmei Jia
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, T., Wang, J., Chen, L., Zhang, X., Mou, T., An, X., Zhang, J., Zhang, X., Deuther-Conrad, W., Huang, Y., & Jia, H. (2023). Development of a Highly Specific 18 F-Labeled Radioligand for Imaging of the Sigma-2 Receptor in Brain Tumors. Journal of Medicinal Chemistry, 66(18), 12840-12857. https://doi.org/10.1021/acs.jmedchem.3c00735
Vancouver
Wang T, Wang J, Chen L, Zhang X, Mou T, An X, et al. Development of a Highly Specific 18 F-Labeled Radioligand for Imaging of the Sigma-2 Receptor in Brain Tumors. Journal of Medicinal Chemistry. 2023;66(18):12840-12857. doi:10.1021/acs.jmedchem.3c00735
BibTeX
@article{Wang2023,
author = {Wang, Tao and Wang, Jingqi and Chen, Leyuan and Zhang, Xiaojun and Mou, Tiantian and An, Xiaodan and Zhang, Jinming and Zhang, Xiaoli and Deuther-Conrad, Winnie and Huang, Yiyun and Jia, Hongmei},
title = {Development of a Highly Specific 18 F-Labeled Radioligand for Imaging of the Sigma-2 Receptor in Brain Tumors},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {18},
pages = {12840--12857},
doi = {10.1021/acs.jmedchem.3c00735}
}
EUVIMED